{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:23:09Z","timestamp":1772166189151,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite strong antiplatelet therapy with ticagrelor, serious ischemic events still occur in patients with acute coronary syndrome (ACS). The predictability of platelet reactivity to the residual risk of ischemic events during ticagrelor treatment remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to investigate the predictability of the thromboelastography (TEG)-measured adenosine disphosphate (ADP)-induced platelet inhibition rate (ADP%) to the ischemic events in ticagrelor-treated patients with ACS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of ticagrelor-treated patients with ACS were consecutively recruited. ADP% was measured by TEG after 3\u2009days of ticagrelor maintenance treatment. The primary ischemic event was defined as rehospitalization for unstable angina (UA) within 1\u2009year, and the secondary ischemic event was a composite of the primary ischemic event plus all-cause death, nonfatal myocardial infarction (MI), stent thrombosis, stroke, and unplanned revascularization within 1\u2009year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 751 eligible patients with ACS were included in the analysis, with 336 patients randomly assigned to the derivation group and 415 to the validation group. The overall rates of primary and secondary ischemic events were 14.51% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009109) and 16.91% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009127), respectively. Compared to the patients without ischemic events, those with ischemic events had a significantly lower ADP% both in the derivation group (for primary ischemic events: 66.05% vs. 92.80%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; for secondary ischemic events: 66.05% vs. 93.20%, p\u2009&lt;\u20090.001) and in the validation group (for primary ischemic events: 66.40% vs. 89.20%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; for secondary ischemic events: 66.90% vs. 89.20%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Receiver operating characteristic curve (ROC) analysis showed that an ADP%\u2009&lt;\u200976% was the optimal cut-off value for predicting 1-year primary ischemic events, with an area under the curve (AUC) of 0.80 (95% CI: 0.72\u20130.86,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in the derivation group and 0.77 (95% CI: 0.69\u20130.85,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in the validation group. The multivariate Cox regression hazard analysis consistently identified an ADP%\u2009&lt;\u200976% as an independent predictor of primary ischemic events in the derivation group (HR: 8.21, 95% CI: 4.82\u201313.99,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and in the validation group (HR: 6.34 95% CI: 3.32\u201312.11,\n                      <jats:italic>p\u2009&lt;<\/jats:italic>\n                      \u00a00.001). There was also a strong association between an ADP% &lt;\u200976 and the occurrence of secondary ischemic events in the derivation group (HR: 7.33, 95% CI: 4.47\u201312.00,\n                      <jats:italic>p\u2009&lt;<\/jats:italic>\n                      \u00a00.001) and in the validation group (HR: 4.76, 95% CI: 2.73\u20138.32,\n                      <jats:italic>p\u2009&lt;<\/jats:italic>\n                      \u00a00.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The ADP-induced platelet inhibition rate measured by TEG could predict ischemic events in ticagrelor-treated patients with ACS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12959-022-00380-4","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T04:05:07Z","timestamp":1650513907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndrome"],"prefix":"10.1186","volume":"20","author":[{"given":"Yuting","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangxun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"issue":"5","key":"380_CR1","doi-asserted-by":"publisher","first-page":"e477","DOI":"10.1097\/MJT.0000000000001013","volume":"27","author":"T Akhtar","year":"2020","unstructured":"Akhtar T, Bandyopadhyay D, Ghosh RK, Aronow WS, Lavie CJ, Yadav N. Advances in the pharmacogenomics of antiplatelet therapy. Am J Ther. 2020;27(5):e477\u201384. https:\/\/doi.org\/10.1097\/MJT.0000000000001013.","journal-title":"Am J Ther"},{"issue":"68","key":"380_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"2016","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2016;2016(68):1082\u2013115. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.513.","journal-title":"J Am Coll Cardiol"},{"issue":"40","key":"380_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy855","volume":"2019","author":"FJ Neumann","year":"2018","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018;2019(40):87\u2013165. https:\/\/doi.org\/10.1093\/eurheartj\/ehy855.","journal-title":"Eur Heart J"},{"issue":"3","key":"380_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamainternmed.2019.6447","volume":"180","author":"RD Turgeon","year":"2020","unstructured":"Turgeon RD, Koshman SL, Youngson E, Har B, Wilton SB, James MT, et al. Association of Ticagrelor vs Clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA Intern Med. 2020;180(3):420\u20138. https:\/\/doi.org\/10.1001\/jamainternmed.2019.6447.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"380_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ccd.26279","volume":"88","author":"C Larmore","year":"2016","unstructured":"Larmore C, Effron MB, Molife C, DeKoven M, Zhu Y, Lu J, et al. Real-World Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States. Catheter Cardiovasc Interv. 2016;88(4):535\u201344. https:\/\/doi.org\/10.1002\/ccd.26279.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"380_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40256-017-0255-y","volume":"18","author":"MB Effron","year":"2018","unstructured":"Effron MB, Nair KV, Molife C, Keller SY, Page RL 2nd, Simeone JC, et al. One-year clinical effectiveness comparison of Prasugrel with Ticagrelor: results from a retrospective observational study using an integrated claims database. Am J Cardiovasc Drugs. 2018;18(2):129\u201341. https:\/\/doi.org\/10.1007\/s40256-017-0255-y.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"380_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11936-009-0003-y","volume":"11","author":"PA Gurbel","year":"2009","unstructured":"Gurbel PA, Tantry US. Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease. Curr Treat Options Cardiovasc Med. 2009;11(1):22\u201332. https:\/\/doi.org\/10.1007\/s11936-009-0003-y.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"10","key":"380_CR8","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","volume":"46","author":"PA Gurbel","year":"2005","unstructured":"Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol. 2005;46(10):1820\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2005.07.041.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"380_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ahj.2010.06.004","volume":"160","author":"D Aradi","year":"2010","unstructured":"Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J. 2010;160(3):543\u201351. https:\/\/doi.org\/10.1016\/j.ahj.2010.06.004.","journal-title":"Am Heart J"},{"issue":"10104","key":"380_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(17)32155-4.","journal-title":"Lancet"},{"issue":"8","key":"380_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2010.181","volume":"303","author":"NJ Breet","year":"2010","unstructured":"Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754\u201362. https:\/\/doi.org\/10.1001\/jama.2010.181.","journal-title":"JAMA"},{"issue":"2","key":"380_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ahj.2010.05.034","volume":"160","author":"PA Gurbel","year":"2010","unstructured":"Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J. 2010;160(2):346\u201354. https:\/\/doi.org\/10.1016\/j.ahj.2010.05.034.","journal-title":"Am Heart J"},{"issue":"7","key":"380_CR13","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1055\/a-1326-5110","volume":"121","author":"M Laine","year":"2021","unstructured":"Laine M, Panagides V, Frere C, Cuisset T, Gouarne C, Jouve B, et al. On-Ticagrelor platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Thromb Haemost. 2021;121(7):923\u201330. https:\/\/doi.org\/10.1055\/a-1326-5110.","journal-title":"Thromb Haemost"},{"issue":"12","key":"380_CR14","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1111\/jth.14592","volume":"17","author":"M Laine","year":"2019","unstructured":"Laine M, Panagides V, Frere C, Cuisset T, Gouarne C, Jouve B, et al. Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome. J Thromb Haemost. 2019;17(12):2188\u201395. https:\/\/doi.org\/10.1111\/jth.14592.","journal-title":"J Thromb Haemost"},{"issue":"14","key":"380_CR15","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","volume":"70","author":"C Patrono","year":"2017","unstructured":"Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, et al. Antiplatelet agents for the treatment and prevention of coronary Atherothrombosis. J Am Coll Cardiol. 2017;70(14):1760\u201376. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.037.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"380_CR16","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation. 2009;120(25):2577\u201385. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.912550.","journal-title":"Circulation"},{"issue":"4","key":"380_CR17","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1161\/ATVBAHA.118.310224","volume":"38","author":"SP Grover","year":"2018","unstructured":"Grover SP, Bergmeier W, Mackman N. Platelet signaling pathways and new inhibitors. Arterioscler Thromb Vasc Biol. 2018;38(4):e28\u201335. https:\/\/doi.org\/10.1161\/ATVBAHA.118.310224.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"380_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41401-019-0278-9","volume":"41","author":"HY Wu","year":"2020","unstructured":"Wu HY, Zhang C, Zhao X, Qian JY, Wang QB, Ge JB. Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography. Acta Pharmacol Sin. 2020;41(2):192\u20137. https:\/\/doi.org\/10.1038\/s41401-019-0278-9.","journal-title":"Acta Pharmacol Sin"},{"issue":"21","key":"380_CR19","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1161\/CIRCULATIONAHA.117.030190","volume":"137","author":"YD Tang","year":"2018","unstructured":"Tang YD, Wang W, Yang M, Zhang K, Chen J, Qiao S, et al. Randomized comparisons of double-dose Clopidogrel or adjunctive Cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE trial. Circulation. 2018;137(21):2231\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030190.","journal-title":"Circulation"},{"issue":"1","key":"380_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12933-020-01146-w","volume":"19","author":"X Zhao","year":"2020","unstructured":"Zhao X, Li Q, Tu C, Zeng Y, Ye Y. High glycated albumin is an independent predictor of low response to clopidogrel in ACS patients: a cross-sectional study. Cardiovasc Diabetol. 2020;19(1):171. https:\/\/doi.org\/10.1186\/s12933-020-01146-w.","journal-title":"Cardiovasc Diabetol"},{"issue":"17","key":"380_CR21","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344\u201351. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.685313.","journal-title":"Circulation"},{"key":"380_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/HPC.0b013e3182846e16","volume":"12","author":"CP Cannon","year":"2013","unstructured":"Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT Jr, Drozda JP Jr, et al. 2013 ACCF\/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Crit Pathw Cardiol. 2013;12:65\u2013105.","journal-title":"Crit Pathw Cardiol"},{"issue":"1","key":"380_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/0141076816680121","volume":"110","author":"AP Coupland","year":"2017","unstructured":"Coupland AP, Thapar A, Qureshi MI, Jenkins H, Davies AH. The definition of stroke. J R Soc Med. 2017;110(1):9\u201312. https:\/\/doi.org\/10.1177\/0141076816680121.","journal-title":"J R Soc Med"},{"issue":"14","key":"380_CR24","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJMoa1415516","volume":"372","author":"PS Douglas","year":"2015","unstructured":"Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372(14):1291\u2013300. https:\/\/doi.org\/10.1056\/NEJMoa1415516.","journal-title":"N Engl J Med"},{"issue":"29","key":"380_CR25","doi-asserted-by":"publisher","first-page":"e1713","DOI":"10.1016\/j.cjca.2013.09.016","volume":"2013","author":"D Alexopoulos","year":"1743","unstructured":"Alexopoulos D, Xanthopoulou I, Stavrou K, Hahalis G, Davlouros P. Platelet reactivity measurements reveal patient noncompliance during ticagrelor maintenance therapy. Can J Cardiol. 1743;2013(29):e1713\u201344. https:\/\/doi.org\/10.1016\/j.cjca.2013.09.016.","journal-title":"Can J Cardiol"},{"issue":"1","key":"380_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ijcard.2013.01.191","volume":"168","author":"D Alexopoulos","year":"2013","unstructured":"Alexopoulos D, Xanthopoulou I, Siapika A, Tsoni E, Stavrou K, Theodoropoulos KC, et al. Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients. Int J Cardiol. 2013;168(1):629\u201330. https:\/\/doi.org\/10.1016\/j.ijcard.2013.01.191.","journal-title":"Int J Cardiol"},{"issue":"4","key":"380_CR27","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ahj.2014.06.026","volume":"168","author":"D Alexopoulos","year":"2014","unstructured":"Alexopoulos D, Xanthopoulou I, Storey RF, Bliden KP, Tantry US, Angiolillo DJ, et al. Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. Am Heart J. 2014;168(4):530\u20136. https:\/\/doi.org\/10.1016\/j.ahj.2014.06.026.","journal-title":"Am Heart J"},{"issue":"20","key":"380_CR28","doi-asserted-by":"publisher","first-page":"20085","DOI":"10.18632\/aging.103452","volume":"12","author":"Y Yang","year":"2020","unstructured":"Yang Y, Chen W, Pan Y, Yan H, Meng X, Liu L, et al. Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA. Aging (Albany NY). 2020;12(20):20085\u201394. https:\/\/doi.org\/10.18632\/aging.103452.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"380_CR29","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.thromres.2013.04.030","volume":"132","author":"M Laine","year":"2013","unstructured":"Laine M, Toesca R, Berbis J, Frere C, Barnay P, Pansieri M, et al. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention. Thromb Res. 2013;132(1):e15\u20138. https:\/\/doi.org\/10.1016\/j.thromres.2013.04.030.","journal-title":"Thromb Res"},{"issue":"11","key":"380_CR30","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"},{"issue":"11","key":"380_CR31","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/clc.23074","volume":"41","author":"XY Li","year":"2018","unstructured":"Li XY, Su GH, Wang GX, Hu HY, Fan CJ. Switching from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction undergoing successful percutaneous coronary intervention in real-world China: occurrences, reasons, and long-term clinical outcomes. Clin Cardiol. 2018;41(11):1446\u201354. https:\/\/doi.org\/10.1002\/clc.23074.","journal-title":"Clin Cardiol"},{"issue":"6","key":"380_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jcin.2008.08.018","volume":"1","author":"T Cuisset","year":"2008","unstructured":"Cuisset T, Frere C, Quilici J, Morange PE, Mouret JP, Bali L, et al. Glycoprotein IIb\/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv. 2008;1(6):649\u201353. https:\/\/doi.org\/10.1016\/j.jcin.2008.08.018.","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"380_CR33","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.cjca.2019.05.003","volume":"35","author":"A Karathanos","year":"2019","unstructured":"Karathanos A, Lin Y, Dannenberg L, Parco C, Schulze V, Brockmeyer M, et al. Routine glycoprotein IIb\/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: a Meta-analysis. Can J Cardiol. 2019;35(11):1576\u201388. https:\/\/doi.org\/10.1016\/j.cjca.2019.05.003.","journal-title":"Can J Cardiol"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-022-00380-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-022-00380-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-022-00380-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T17:07:35Z","timestamp":1650560855000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-022-00380-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["380"],"URL":"https:\/\/doi.org\/10.1186\/s12959-022-00380-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1431361\/v1","asserted-by":"object"}]},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"8 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the institutional ethics committee of the Chinese PLA General Hospital. The patients\/participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Yes","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}